Eli Lilly and Company, based in Indianapolis, is one of the largest pharmaceutical companies in the world, committed to developing a growing portfolio of best-in-class and first-in-class pharmaceutical products. Eli Lilly has an exclusive worldwide licence to commercialise Axiron®, which it launched in the United States in April 2011.
Perrigo is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter and prescription pharmaceuticals, nutritional products, and active pharmaceutical ingredients, as well as receives royalties from product sales. Perrigo has sub-licensed Evamist® for commercialisation in the US from Lumara Health, who licensed Evamist® from Acrux.
Gedeon Richter is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. With its widely acknowledged steroid chemistry expertise, Gedeon Richter is a significant player in the female healthcare field worldwide. Acrux has licensed manufacturing and marketing rights for its estradiol product to Gedeon Richter for all territories excluding the United States, South Korea, Southern Africa, Switzerland and Australasia.
Elanco, a division of Eli Lilly, is one of the top 10 companies in veterinary healthcare. Elanco has licensed Acrux's technology to develop and commercialise animal health products in global markets. The first product, Recuvyra®, has been approved and launched in both US and Europe.